Date | Dividend Yield | Free Cash Flow Yield | Earnings Yield | Enterprise Value (EV) |
---|
CEO | Mr. Kazuhide Nakatomi |
IPO Date | Jan. 1, 2001 |
Location | Japan |
Headquarters | 408, Tashiro Daikan-machi |
Employees | 2,759 |
Sector | Health Care |
Industries |
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, transdermal analgesic anti-inflammatory drug; patches for female hormone, asthma treatment, and treatment for overactive bladders. In addition, the company manufactures and sells drugs under MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Further, it provides HFT-290, a transdermal patch for cancer pain. The company sells its products in the United States and Asia. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.
Past 5 years
USD 14.22
USD 3.49
USD 10.35
USD 43.03
StockViz Staff
January 15, 2025
Any question? Send us an email